Interleukin-6 polypeptide inhibitor and its application
A peptide inhibitor, interleukin technology, applied in the direction of peptides, anti-inflammatory agents, peptide/protein components, etc., to inhibit physiological or pathological effects, prevent or treat rheumatoid arthritis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0015] Immunoprotective effect of interleukin-6 polypeptide inhibitor 3 in collagen-induced mouse arthritis animal model
[0016] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of interleukin-6 polypeptide inhibitor 3 on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, body weight 18-22 g, were randomly divided into 6 groups, namely normal control group, model control group, peptide inhibitor 3 low, middle and high dosage groups (0.4, 0.8 , 1.6 mg / kg) and positive drug control group (methotrexate 2 mg / kg). In addition to the normal group, the mouse CIA model was established in each experimental group on day 0 by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and placing it in a refrigerator...
Embodiment 2
[0021] Protective Effect of Interleukin-6 Peptide Inhibitor 3 on In Vivo Immunoprotective Effects of Adjuvanted Rat Arthritis Animal Model
[0022] To construct an adjuvant rat arthritis animal model to study the therapeutic effect of interleukin-6 polypeptide inhibitor 3 on adjuvant arthritis (AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008 -0016), male, body weight 140 g-160 g, were randomly divided into 6 groups, namely normal control group, model control group, interleukin-6 peptide inhibitor 3 low, middle and high dosage groups (0.2, 0.4, 0.8 mg / kg) and positive drug control group (methotrexate 1 mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10 mg / ml) into the left hindquarters of the rat...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com